The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation

Chronic inflammatory diseases often affect women of childbearing age. Since biologic and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are more available, their use during conception, pregnancy and lactation has become a matter of concern. Current studies prove the...

Full description

Saved in:
Bibliographic Details
Published in:Postȩpy dermatologii i alergologii 2020-01, Vol.37 (3), p.306-312
Main Authors: Góralczyk, Alicja, Kolossa, Katarzyna, Waszczak-Jeka, Marzena, Adamczak, Rafał, Jeka, Sławomir
Format: Article
Language:English
Subjects:
Breastfeeding & lactation
Inflammatory diseases
Pregnancy
Review Paper
Tumor necrosis factor-TNF
Womens health
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic inflammatory diseases often affect women of childbearing age. Since biologic and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are more available, their use during conception, pregnancy and lactation has become a matter of concern. Current studies prove the safety of innovative therapy in pregnant women and may contribute to its wider use than before in pregnancy and lactation. It mainly concerns tumour necrosis factor a (TNF-a) inhibitors. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. We present up-to-date knowledge of bDMARDs and tsDMARDs safety in pregnant and breastfeeding women.
ISSN:1642-395X
2299-0046
DOI:10.5114/ada.2020.96294